SNRPB2 facilitates esophageal squamous cell carcinoma oncogenesis and progression via E2F4 stabilization
Year: 2025
Type: article
Abstract: Introduction: Esophageal cancer (ESCA) has poor prognosis. Small nuclear ribonucleoprotein polypeptide B2 (SNRPB2) involves in pre-mRNA splicing a component of the spliceosome. However, the potential role of SNRPB2 in tumors remains poorly understood. This study aimed to determine the clinical relevance and prognostic value of SNRPB2 in patients with ESCA. Methods SNRPB2 mRNA expression levels and genetic alterations were analyzed using GEPIA2 and cBioPortal. The SNRPB2 protein were detected by immunohistochemical staining using paraffin-embedded tissue specimens of esophageal squamous cell carcinoma (ESCC). Cell experiments were performed to verify the role of SNRPB2 in ESCC cells. TIMER, GO, and GSEA analyses were performed to investigate potential biological functions of SNRPB2. Cycloheximide (CHX) chase was used to test protein stability. Results SNRPB2 mRNA was highly expressed in ESCA and associated with tumor progression and clinical prognosis. SNRPB2 protein was highly expressed in ESCC and significantly correlated with vessel carcinoma embolus, lymph node metastasis, clinical stage, and tumor grade. in vitro and in vivo experiments showed that the knockdown of SNRPB2 significantly suppressed proliferation, migration, and invasion. GSEA showed that SNRPB2 inhibits the Rb/E2F pathway. SNRPB2 positively correlates with E2F4 by increasing E2F4 protein stability. E2F4 overexpression dramatically eliminated the effects of SNRPB2 knockdown on ESCC tumor progression. Conclusion SNRPB2 promotes the proliferation, migration, and invasion of ESCC cells by increasing E2F4 protein stability. SNRPB2 has a prognostic role and immunoregulatory potential in ESCA, and is an important factor for prediction, evaluation, and individualized treatment.
Source: Frontiers in Immunology
Authors: Feng Xu, Chen-cheng Zhu, Chen Lu, Guang-yao Ning, Ren-quan Zhang
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W4411462725